Newronika Receives Investigational Device Exemption (IDE) from FDA to Initiate U.S. Clinical Trial of Adaptive DBS System

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Newronika-IDE-FDA

More Like This

PR Newswire associated0

Newronika Receives CE Mark Approval for AlphaDBS, Advancing Adaptive Deep Brain Stimulation for Parkinson's Disease

PR Newswire associated0

Newronika Closes €13.6 Million Series B Financing to Accelerate Development of Adaptive DBS Platform

PR Newswire associated0

Potential Add-on Treatment for Patients with Parkinson's Disease: Stimvia Completes Pilot Study and Announces Promising Initial Results

ONWARD Medical to Advance Parkinson’s Disease Pipeline with Support from The Michael J. Fox Foundation and US Department of Defense

PR Newswire associated0

QuantalX Neuroscience Announces CE MDR Approval, Making Brain Health Assessment Available in the EU

Evolution Optiks Successfully Completes Data Collection in Clinical Study of Neuro-Optical Testing Device

PR Newswire associated0

Endotronix Receives IDE Approval for the Market Expanding PROACTIVE-HF 2 Clinical Trial

PR Newswire associated0

QuantalX Secures FDA Clearance for its breakthrough Delphi stimulator, advancing direct brain health diagnosis at the point of care